Can wearable glucose monitors reveal hidden risks in dialysis patients with diabetes?
NCT ID NCT07790276
First seen Aug 27, 2026 · Last updated Aug 28, 2026 · Updated 1 time
Summary
This study follows 100 adults with diabetes who are on peritoneal dialysis or about to start it. Researchers use a continuous glucose monitor to track blood sugar levels over time. They will look for links between glucose patterns and health events like hospitalizations, heart problems, and death over 12 months. The goal is to see if this monitoring method offers better insight than traditional blood tests.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Continuous glucose monitoring system (Sibionics GS3 CGM)
- What this could lead to
- If it works, this could improve how doctors manage blood sugar in people with diabetes on peritoneal dialysis, potentially reducing hospitalizations and heart problems.
- What could go wrong
- This is an observational study, so it cannot prove cause and effect. The results may not apply to everyone, and the device may have accuracy issues in this population.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults with diabetes and stage 5 chronic kidney disease who are receiving peritoneal dialysis or are planned to initiate peritoneal dialysis within 3 months.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria: 1. Stage 5 CKD patients 1. who have received PD for at least 3 months, OR 2. who are planned for PD within the next 3 months. 2. Age 18-80 years old 3. Known history of type 1 or type 2 diabetes for at least 3 months 4. Women who are not pregnant, lactating or planning a pregnancy during their participation in the clinical study. 5. Willingness, ability and commitment to comply with the testing, procedure and follow-up outlined in this protocol including (but not limited to) frequency of clinic visits and use of pre-specified glucose monitoring devices. 6. Willingness to abstain from swimming during their participation in the measurement phase. 7. In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a good study candidate. 8. Written informed consent to participate in the study provided by the patient. Exclusion criteria: 1. Patients who are planning to switch to hemodialysis or renal transplant in the coming 3 months 2. Life expectancy \<6 months 3. Extensive skin changes/diseases that preclude wearing the required number of devices on normal skin at the proposed application sites 4. HbA1c \> 11% at enrolment 5. Currently pregnant, as demonstrated by a positive pregnancy test at screening for women of reproductive potential. 6. Any active acute or chronic disease or condition that, in the opinion of the investigator, might interfere with the performance of this study. 7. Any active acute or chronic infectious disease that, in the opinion of the investigator, would pose an excessive risk to study staff. 8. Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device. 9. Have a known allergy to medical-grade adhesives or known hypersensitivity to any of the products used in the study. 10. Have MRI scan, CT scan, or diathermy scheduled during the proposed period of sensor wearing during the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Continuous glucose monitoring are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Medicine and Therapeutics, The Chinese University of Hong Kong
Hong Kong, Hong Kong
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Clinical and biological responses to repeated administration of low-dose Interleukin-2 in patients with type 1 diabetes and a residual insulin secretion
- Cost-Effectiveness and implementation of integrated Diabetes-Oral health care in oman: a health belief Model-Based intervention to enhance clinical, behavioral, and exploratory oral microbiome in health system outcomes in type 2 diabetes
- Fibrinogen to albumin ratio (FAR) as a risk factor for type 2 diabetic Nephropathy(DN)
- A protein clue may spot dialysis membrane failure before it starts
- Can a smart insulin pump tailored for pregnancy protect mothers and babies?
- Can an automated pancreas system make type 1 diabetes safer in the real world?